{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T23:20:26Z","timestamp":1773271226159,"version":"3.50.1"},"reference-count":69,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2016,10,6]],"date-time":"2016-10-06T00:00:00Z","timestamp":1475712000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001767","name":"National Foundation for Cancer Research","doi-asserted-by":"publisher","award":["I5-A537"],"award-info":[{"award-number":["I5-A537"]}],"id":[{"id":"10.13039\/100001767","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Malcolm Hewitt Wiener Foundation","award":["[none]"],"award-info":[{"award-number":["[none]"]}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["T32HL094284"],"award-info":[{"award-number":["T32HL094284"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0162978","type":"journal-article","created":{"date-parts":[[2016,10,6]],"date-time":"2016-10-06T13:38:24Z","timestamp":1475761104000},"page":"e0162978","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["Anti-Epidermal Growth Factor Receptor Gene Therapy for Glioblastoma"],"prefix":"10.1371","volume":"11","author":[{"given":"Martin J.","family":"Hicks","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria J.","family":"Chiuchiolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Ballon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan P.","family":"Dyke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Aronowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Funato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviane","family":"Tabar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Havlicek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolan","family":"Sondhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen M.","family":"Kaminsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald G.","family":"Crystal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,10,6]]},"reference":[{"issue":"6","key":"ref1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary","volume":"131","author":"DN Louis","year":"2016","journal-title":"Acta Neuropathol"},{"issue":"Suppl 4","key":"ref2","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/nov189","article-title":"CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008\u20132012","volume":"17","author":"QT Ostrom","year":"2015","journal-title":"Neuro Oncol"},{"issue":"10","key":"ref3","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"R Stupp","year":"2005","journal-title":"N Engl J Med"},{"issue":"9","key":"ref4","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1158\/1078-0432.CCR-14-1328","article-title":"New strategies in glioblastoma: exploiting the new biology","volume":"21","author":"HA Fine","year":"2015","journal-title":"Clin Cancer Res"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/B978-0-444-53502-3.00004-5","article-title":"Glioblastoma","volume":"105","author":"M Penas-Prado","year":"2012","journal-title":"Handb Clin Neurol"},{"issue":"19","key":"ref6","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1158\/1078-0432.CCR-14-0822","article-title":"Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma","volume":"20","author":"A Omuro","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"6","key":"ref7","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00401-015-1432-1","article-title":"Glioblastoma: pathology, molecular mechanisms and markers","volume":"129","author":"K Aldape","year":"2015","journal-title":"Acta Neuropathol"},{"issue":"5","key":"ref8","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"R Stupp","year":"2009","journal-title":"Lancet Oncol"},{"issue":"10","key":"ref9","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1073\/pnas.0804543106","article-title":"Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR","volume":"106","author":"K Al-Nedawi","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"ref10","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/nrc3918","article-title":"Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma","volume":"15","author":"FB Furnari","year":"2015","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"ref11","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/ncb1800","article-title":"Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers","volume":"10","author":"J Skog","year":"2008","journal-title":"Nat Cell Biol"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.yexcr.2011.04.001","article-title":"Maintenance of EGFR and EGFRvIII expressions in an in vivo and in vitro model of human glioblastoma multiforme","volume":"317","author":"MT Stockhausen","year":"2011","journal-title":"Exp Cell Res"},{"issue":"4","key":"ref13","first-page":"379","article-title":"PET imaging of glioblastoma multiforme EGFR expression for therapeutic decision guidance","volume":"5","author":"E Wehrenberg-Klee","year":"2015","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"26","key":"ref14","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1200\/JCO.2007.11.8554","article-title":"Chemoradiotherapy in malignant glioma: standard of care and future directions","volume":"25","author":"R Stupp","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1179\/ACB.66.1.2062508","article-title":"Epidermal growth factor receptor targeted therapies for solid tumours","volume":"66","author":"M Van den Eynde","year":"2011","journal-title":"Acta Clin Belg"},{"issue":"1","key":"ref16","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11307-014-0773-9","article-title":"IND-directed safety and biodistribution study of intravenously injected cetuximab-IRDye800 in cynomolgus macaques","volume":"17","author":"KR Zinn","year":"2015","journal-title":"Mol Imaging Biol"},{"issue":"7","key":"ref17","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrd1445","article-title":"Cetuximab","volume":"3","author":"J Graham","year":"2004","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"ref18","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.clinthera.2013.08.007","article-title":"Epidermal growth factor receptor: pathway, therapies, and pipeline","volume":"35","author":"JR Goffin","year":"2013","journal-title":"Clin Ther"},{"issue":"1","key":"ref19","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1124\/dmd.112.048322","article-title":"Function of the blood-brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma","volume":"41","author":"S Agarwal","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12964-015-0098-6","article-title":"Therapeutic control and resistance of the EGFR-driven signaling network in glioblastoma","volume":"13","author":"F Azuaje","year":"2015","journal-title":"Cell Commun Signal"},{"key":"ref21","article-title":"Antibody therapies in CNS diseases","author":"PO Freskgard","year":"2016","journal-title":"Neuropharmacology"},{"issue":"1","key":"ref22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1158\/0008-5472.CAN-08-2356","article-title":"A new model for prediction of drug distribution in tumor and normal tissues: pharmacokinetics of temozolomide in glioma patients","volume":"69","author":"L Rosso","year":"2009","journal-title":"Cancer Res"},{"issue":"4","key":"ref23","first-page":"167","article-title":"The Blood-Brain Barrier Challenge for the Treatment of Brain Cancer, Secondary Brain Metastases, and Neurological Diseases","volume":"12","author":"UH Weidle","year":"2015","journal-title":"Cancer Genomics Proteomics"},{"issue":"1","key":"ref24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/cgt.2014.58","article-title":"Genetic modification of neurons to express bevacizumab for local anti-angiogenesis treatment of glioblastoma","volume":"22","author":"MJ Hicks","year":"2015","journal-title":"Cancer Gene Ther"},{"issue":"3","key":"ref25","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1089\/humc.2013.239","article-title":"Comparative efficacy and safety of multiple routes of direct CNS administration of adeno-associated virus gene transfer vector serotype rh.10 expressing the human arylsulfatase A cDNA to nonhuman primates","volume":"25","author":"JB Rosenberg","year":"2014","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"2","key":"ref26","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1089\/humc.2014.139","article-title":"Intracerebral Gene Therapy Using AAVrh.10-hARSA Recombinant Vector to Treat Patients with Early-Onset Forms of Metachromatic Leukodystrophy: Preclinical Feasibility and Safety Assessments in Nonhuman Primates","volume":"26","author":"M Zerah","year":"2015","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"5","key":"ref27","doi-asserted-by":"crossref","first-page":"699","DOI":"10.4161\/mabs.25423","article-title":"Correct primary structure assessment and extensive glyco-profiling of cetuximab by a combination of intact, middle-up, middle-down and bottom-up ESI and MALDI mass spectrometry techniques","volume":"5","author":"D Ayoub","year":"2013","journal-title":"MAbs"},{"issue":"5","key":"ref28","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nbt1087","article-title":"Stable antibody expression at therapeutic levels using the 2A peptide","volume":"23","author":"J Fang","year":"2005","journal-title":"Nat Biotechnol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"16002","DOI":"10.1038\/mtm.2016.2","article-title":"Manufacturing of recombinant adeno-associated viral vectors for clinical trials","volume":"3","author":"N Clement","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"16","key":"ref30","doi-asserted-by":"crossref","first-page":"7727","DOI":"10.1073\/pnas.91.16.7727","article-title":"A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity","volume":"91","author":"R Nishikawa","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/978-1-60761-901-7_11","article-title":"In vivo imaging of the dynamics of different variants of EGFR in glioblastomas","volume":"680","author":"K Shah","year":"2011","journal-title":"Methods Mol Biol"},{"issue":"8","key":"ref32","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/gt.2010.87","article-title":"AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors","volume":"17","author":"M Watanabe","year":"2010","journal-title":"Gene Ther"},{"issue":"3","key":"ref33","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s10571-015-0293-4","article-title":"Extracellular Vesicles and MicroRNAs: Their Role in Tumorigenicity and Therapy for Brain Tumors","volume":"36","author":"A Bronisz","year":"2016","journal-title":"Cell Mol Neurobiol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-3-319-12048-5_8","article-title":"Novel chemotherapeutic approaches in adult high-grade gliomas","volume":"163","author":"JT Jordan","year":"2015","journal-title":"Cancer Treat Res"},{"issue":"Suppl 2","key":"ref35","doi-asserted-by":"crossref","first-page":"ii24","DOI":"10.1093\/neuonc\/nou355","article-title":"Sui generis: gene therapy and delivery systems for the treatment of glioblastoma","volume":"17","author":"JR Kane","year":"2015","journal-title":"Neuro Oncol"},{"issue":"2","key":"ref36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1136\/jnnp-2012-302946","article-title":"The art of gene therapy for glioma: a review of the challenging road to the bedside","volume":"84","author":"A Tobias","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"ref37","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.3390\/cancers5041271","article-title":"Strategies in gene therapy for glioblastoma","volume":"5","author":"A Kwiatkowska","year":"2013","journal-title":"Cancers (Basel)"},{"issue":"4","key":"ref38","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.trsl.2012.11.003","article-title":"Current status of gene therapy for brain tumors","volume":"161","author":"AM Murphy","year":"2013","journal-title":"Transl Res"},{"issue":"5","key":"ref39","first-page":"419","article-title":"Viral vectors as therapeutic agents for glioblastoma","volume":"7","author":"M Aghi","year":"2005","journal-title":"Curr Opin Mol Ther"},{"issue":"9","key":"ref40","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1517\/14712598.2014.915307","article-title":"Adenoviral vector-mediated gene therapy for gliomas: coming of age","volume":"14","author":"MG Castro","year":"2014","journal-title":"Expert Opin Biol Ther"},{"issue":"21","key":"ref41","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/sj.gt.3301311","article-title":"Immune response induced by retrovirus-mediated HSV-tk\/GCV pharmacogene therapy in patients with glioblastoma multiforme","volume":"7","author":"NG Rainov","year":"2000","journal-title":"Gene Ther"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2052-8426-2-21","article-title":"Gene therapy for malignant glioma","volume":"2","author":"H Okura","year":"2014","journal-title":"Mol Cell Ther"},{"issue":"4","key":"ref43","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ymthe.2005.07.357","article-title":"Gene therapy for malignant glioma: current clinical status","volume":"12","author":"KJ Pulkkanen","year":"2005","journal-title":"Mol Ther"},{"issue":"5","key":"ref44","first-page":"245","article-title":"Timing of ganciclovir administration in glioma gene therapy using HSVtk gene-transduced mesenchymal stem cells","volume":"8","author":"S Amano","year":"2011","journal-title":"Cancer Genomics Proteomics"},{"issue":"3","key":"ref45","doi-asserted-by":"crossref","first-page":"186","DOI":"10.4161\/cam.2.3.6278","article-title":"Gene therapy for high-grade glioma: current approaches and future directions","volume":"2","author":"A Natsume","year":"2008","journal-title":"Cell Adh Migr"},{"issue":"4","key":"ref46","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/gt.2012.62","article-title":"Oncolytic measles virus strains have significant antitumor activity against glioma stem cells","volume":"20","author":"C Allen","year":"2013","journal-title":"Gene Ther"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.coviro.2015.05.007","article-title":"Cytotoxic and immunogenic mechanisms of recombinant oncolytic poliovirus","volume":"13","author":"MC Brown","year":"2015","journal-title":"Curr Opin Virol"},{"issue":"5","key":"ref48","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/sj.neo.7900056","article-title":"HSV-1-based vectors for gene therapy of neurological diseases and brain tumors: part II. Vector systems and applications","volume":"1","author":"A Jacobs","year":"1999","journal-title":"Neoplasia"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s12967-015-0586-x","article-title":"Microglia and astrocytes attenuate the replication of the oncolytic vaccinia virus LIVP 1.1.1 in murine GL261 gliomas by acting as vaccinia virus traps","volume":"13","author":"C Kober","year":"2015","journal-title":"J Transl Med"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fnmol.2014.00050","article-title":"Systemic gene delivery to the central nervous system using Adeno-associated virus","volume":"7","author":"M Bourdenx","year":"2014","journal-title":"Front Mol Neurosci"},{"issue":"R1","key":"ref51","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1093\/hmg\/ddr110","article-title":"Genetic therapy for the nervous system","volume":"20","author":"WJ Bowers","year":"2011","journal-title":"Hum Mol Genet"},{"issue":"1","key":"ref52","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1177\/1073858414521870","article-title":"Adeno-associated virus vectors and neurological gene therapy","volume":"21","author":"DS Ojala","year":"2015","journal-title":"Neuroscientist"},{"issue":"3","key":"ref53","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/sj.mt.6300049","article-title":"Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector","volume":"15","author":"D Sondhi","year":"2007","journal-title":"Mol Ther"},{"issue":"5","key":"ref54","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1089\/hum.2008.022","article-title":"Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA","volume":"19","author":"S Worgall","year":"2008","journal-title":"Hum Gene Ther"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3389\/fnmol.2014.00076","article-title":"Biology of adeno-associated viral vectors in the central nervous system","volume":"7","author":"G Murlidharan","year":"2014","journal-title":"Front Mol Neurosci"},{"key":"ref56","article-title":"Adeno-associated virus (AAV) vectors in cancer gene therapy","author":"JL Santiago-Ortiz","year":"2016","journal-title":"J Control Release"},{"issue":"1","key":"ref57","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s12033-015-9899-5","article-title":"Large-Scale Production of Adeno-Associated Viral Vector Serotype-9 Carrying the Human Survival Motor Neuron Gene","volume":"58","author":"A Rashnonejad","year":"2016","journal-title":"Mol Biotechnol"},{"key":"ref58","first-page":"716813","article-title":"An update in the use of antibodies to treat glioblastoma multiforme","volume":"2013","author":"NY Hernandez-Pedro","year":"2013","journal-title":"Autoimmune Dis"},{"issue":"3","key":"ref59","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11060-009-9972-7","article-title":"Directed evolution of adeno-associated virus for glioma cell transduction","volume":"96","author":"CA Maguire","year":"2010","journal-title":"J Neurooncol"},{"key":"ref60","article-title":"Current Understanding and Treatment of Gliomas","author":"ST Rosen","year":"2015"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.coph.2015.08.002","article-title":"Engineering the AAV capsid to optimize vector-host-interactions","volume":"24","author":"H Buning","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3389\/fimmu.2013.00341","article-title":"Humoral Immune Response to AAV","volume":"4","author":"R Calcedo","year":"2013","journal-title":"Front Immunol"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/978-1-4939-3271-9_10","article-title":"Controlling AAV Tropism in the Nervous System with Natural and Engineered Capsids","volume":"1382","author":"MJ Castle","year":"2016","journal-title":"Methods Mol Biol"},{"issue":"3","key":"ref64","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/gt.2008.170","article-title":"Tailoring the AAV vector capsid for gene therapy","volume":"16","author":"LH Vandenberghe","year":"2009","journal-title":"Gene Ther"},{"issue":"5","key":"ref65","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3892\/mco.2016.816","article-title":"Bevacizumab treatment for newly diagnosed glioblastoma: Systematic review and meta-analysis of clinical trials","volume":"4","author":"P Fu","year":"2016","journal-title":"Mol Clin Oncol"},{"issue":"5","key":"ref66","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1517\/14712598.2014.898060","article-title":"Bevacizumab for the treatment of high-grade glioma: an update after phase III trials","volume":"14","author":"M Khasraw","year":"2014","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"ref67","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.18632\/oncotarget.6320","article-title":"Bevacizumab and radiotherapy for the treatment of glioblastoma: brothers in arms or unholy alliance?","volume":"7","author":"M Niyazi","year":"2016","journal-title":"Oncotarget"},{"key":"ref68","first-page":"1","article-title":"Investigational new drugs for brain cancer","author":"V Staedtke","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"issue":"12","key":"ref69","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1038\/jcbfm.2013.160","article-title":"Brain bioavailability of human intravenous immunoglobulin and its transport through the murine blood-brain barrier","volume":"33","author":"I St-Amour","year":"2013","journal-title":"J Cereb Blood Flow Metab"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0162978","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T05:46:16Z","timestamp":1568439976000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0162978"}},"subtitle":[],"editor":[{"given":"Ilya","family":"Ulasov","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,10,6]]},"references-count":69,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2016,10,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0162978","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,6]]}}}